首页 > 最新文献

Reviews on recent clinical trials最新文献

英文 中文
Hyponatremia Related to Neurocritical Care: Focus on Diagnosis and Therapy: A Systematic Review. 与神经危重症相关的低钠血症:关注诊断和治疗:系统综述。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1574887118666221208161259
Gianluca Mezzini, Stefano Marasco, Alessandro Bertuccio, Gabriele Savioli, Fabio Piccolella, Fabrizio Racca, Andrea Barbanera, Matteo Vitali

Introduction: Hyponatremia is the most frequently occurring electrolyte disorder in neurocritical care and traumatic brain injury, aneurysmal subarachnoid hemorrhage (SAH), neurosurgery, and ischemic stroke are the clinical conditions more often associated with this condition. SIADH and CSWS are the main causes of hyponatremia in neurologically ill patients. Since hyponatremia is a negative prognostic factor for neurocritical patients, early diagnosis and consequent targeted therapy are of fundamental importance. The present review was carried out to provide a brief recap on the main causes and management of hyponatremia in the neurocritical patient.

Methods: A methodical search of the medical literature using the online database MEDLINE was carried out and studies comprising case reports, prospective and retrospective observational studies, or randomized controlled clinical trials in which there is a diagnosis of hyponatremia in neurocritical patients were included.

Results: 18 articles were analyzed, consisting of 8 case reports, 4 case series, 3 prospective trials, 1 retrospective study, and 1 multicenter trial. A total of 1371 patients from 18 studies were included. Patients' average age was 29.28 ± 20.9, respectively. TBI was the main cause of hyponatremia in the literature reviewed; 12 studies were about the relationship between TBI and hyponatremia, 2 studies about stroke, 2 studies about SAH and 1 about hyponatremia postneurosurgical procedure.

Discussion: Hyponatremia is the most common electrolyte disorder in hospitalized patients and the main scenarios of hyponatremic neurocritical patients are subarachnoid hemorrhage, ischemic stroke, traumatic brain injury and iatrogenic hyponatremia due to neurosurgical cases.

Conclusion: Hyponatremia is a frequent finding in neurocritical care and is also a recognized negative prognostic factor leading to increased mortality and ICU length hospitalization. Its diagnosis and therapy are essential for correct neurocritical management. The most common cause of serum sodium abnormality is SIADH, and an early diagnosis for target treatment is paramount to prevent delayed symptoms and complications.

简介:低钠血症是神经危重症和外伤性脑损伤中最常见的电解质紊乱,动脉瘤性蛛网膜下腔出血(SAH)、神经外科手术和缺血性脑卒中是与低钠血症相关的临床情况。SIADH和CSWS是神经系统疾病患者低钠血症的主要原因。由于低钠血症是神经危重症患者的不良预后因素,因此早期诊断和随后的靶向治疗至关重要。本文综述了神经危重症患者低钠血症的主要原因和治疗方法。方法:使用在线数据库MEDLINE对医学文献进行系统检索,研究包括病例报告、前瞻性和回顾性观察性研究,或随机对照临床试验,其中诊断为神经危重症患者低钠血症。结果:共纳入18篇文献,包括8篇病例报告、4个病例系列、3项前瞻性研究、1项回顾性研究和1项多中心试验。共纳入了来自18项研究的1371名患者。患者平均年龄为29.28±20.9岁。在文献综述中,脑外伤是低钠血症的主要原因;12项研究是关于TBI和低钠血症之间的关系,2项研究是关于中风,2项研究是关于SAH, 1项研究是关于神经外科手术后的低钠血症。讨论:低钠血症是住院患者中最常见的电解质紊乱,神经危重症低钠血症的主要情况为蛛网膜下腔出血、缺血性卒中、外伤性脑损伤和神经外科病例引起的医源性低钠血症。结论:低钠血症是神经危重症的常见病,也是公认的导致死亡率和ICU住院时间增加的不良预后因素。其诊断和治疗对正确的神经危重症治疗至关重要。血清钠异常最常见的原因是SIADH,早期诊断和靶向治疗对于预防延迟症状和并发症至关重要。
{"title":"Hyponatremia Related to Neurocritical Care: Focus on Diagnosis and Therapy: A Systematic Review.","authors":"Gianluca Mezzini,&nbsp;Stefano Marasco,&nbsp;Alessandro Bertuccio,&nbsp;Gabriele Savioli,&nbsp;Fabio Piccolella,&nbsp;Fabrizio Racca,&nbsp;Andrea Barbanera,&nbsp;Matteo Vitali","doi":"10.2174/1574887118666221208161259","DOIUrl":"https://doi.org/10.2174/1574887118666221208161259","url":null,"abstract":"<p><strong>Introduction: </strong>Hyponatremia is the most frequently occurring electrolyte disorder in neurocritical care and traumatic brain injury, aneurysmal subarachnoid hemorrhage (SAH), neurosurgery, and ischemic stroke are the clinical conditions more often associated with this condition. SIADH and CSWS are the main causes of hyponatremia in neurologically ill patients. Since hyponatremia is a negative prognostic factor for neurocritical patients, early diagnosis and consequent targeted therapy are of fundamental importance. The present review was carried out to provide a brief recap on the main causes and management of hyponatremia in the neurocritical patient.</p><p><strong>Methods: </strong>A methodical search of the medical literature using the online database MEDLINE was carried out and studies comprising case reports, prospective and retrospective observational studies, or randomized controlled clinical trials in which there is a diagnosis of hyponatremia in neurocritical patients were included.</p><p><strong>Results: </strong>18 articles were analyzed, consisting of 8 case reports, 4 case series, 3 prospective trials, 1 retrospective study, and 1 multicenter trial. A total of 1371 patients from 18 studies were included. Patients' average age was 29.28 ± 20.9, respectively. TBI was the main cause of hyponatremia in the literature reviewed; 12 studies were about the relationship between TBI and hyponatremia, 2 studies about stroke, 2 studies about SAH and 1 about hyponatremia postneurosurgical procedure.</p><p><strong>Discussion: </strong>Hyponatremia is the most common electrolyte disorder in hospitalized patients and the main scenarios of hyponatremic neurocritical patients are subarachnoid hemorrhage, ischemic stroke, traumatic brain injury and iatrogenic hyponatremia due to neurosurgical cases.</p><p><strong>Conclusion: </strong>Hyponatremia is a frequent finding in neurocritical care and is also a recognized negative prognostic factor leading to increased mortality and ICU length hospitalization. Its diagnosis and therapy are essential for correct neurocritical management. The most common cause of serum sodium abnormality is SIADH, and an early diagnosis for target treatment is paramount to prevent delayed symptoms and complications.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9635858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Efficacy of OM-85 in Recurrent Respiratory Tract Infections. OM-85治疗复发性呼吸道感染的疗效观察。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1574887118666230518112806
Pietro Gareri, Caterina Trevisan, Angela Marie Abbatecola, Alba Malara, Raffaele Antonelli Incalzi

Background: In older patients, prevention of acute respiratory tract infections (RTIs) is challenging. Experimental studies have consistently underlined an immune-potentiating effect of the bacterial lysates product OM85, on both cellular and humoral responses.

Objective: This work aimed to assess the potential efficacy of OM-85 for RTIs' prevention in older individuals.

Methods: This explorative longitudinal study included 24 patients aged 65 years or older recruited in the GeroCovid Observational Study- home and outpatient care cohort. For the study purposes, we included 8 patients treated with OM-85 from December 2020 to June 2021 (group A), and a control group of 16 patients, matched for sex and age, who did not receive bacterial lysates (group B). RTIs were recorded from the participants' medical documentation in an e-registry from March 2020 to December 2021.

Results: In 2020, group A experienced a total of 8 RTIs, which affected 6 out of 8 patients (75%); group B reported 21 RTIs, with at least one event in 11 out of 16 patients (68.7%). In 2021, RTIs affected 2 out of 8 patients (25%) in group A (p < 0.02), and 13 out of 16 patients (81.2%) in group B (within this group, 5 patients had two RTIs). The RTIs' cumulative incidence over the observation period significantly differed between groups (66.7% in group A vs. 24.3% in group B; p < 0.002), as well as the decrease in RTIs frequency from 2020 to 2021. No patients in group A were affected by COVID-19 during the observation period, while among controls, two patients had SARS-CoV-2 infection, notwithstanding three doses of vaccine.

Conclusion: This study suggests that bacterial lysates may provide clinical benefits for preventing RTIs. Additional research involving larger cohorts is required to verify the effectiveness of OM-85 in preventing RTIs in older adults.

背景:在老年患者中,预防急性呼吸道感染(RTIs)具有挑战性。实验研究一直强调细菌裂解产物OM85对细胞和体液反应的免疫增强作用。目的:本研究旨在评估OM-85对老年人rti预防的潜在疗效。方法:本探索性纵向研究纳入了24例65岁及以上的老年观察性研究-家庭和门诊护理队列。为了研究目的,我们纳入了8名从2020年12月到2021年6月接受OM-85治疗的患者(A组),以及16名性别和年龄相匹配的对照组,他们没有接受细菌裂解物(B组)。rti从参与者的医疗文件中记录在2020年3月至2021年12月的电子登记处。结果:2020年,A组共发生8例rti, 8例患者中有6例(75%)发生rti;B组报告21例rti, 16例患者中有11例(68.7%)至少发生一次rti。2021年,A组8例患者中有2例(25%)发生RTIs (p < 0.02), B组16例患者中有13例(81.2%)发生RTIs(该组有5例患者发生2例RTIs)。观察期内RTIs的累积发生率在两组间差异显著(A组66.7% vs. B组24.3%;p < 0.002),以及从2020年到2021年rti频率的下降。A组患者在观察期内无COVID-19感染,而对照组患者在接种了3剂疫苗后仍有2例SARS-CoV-2感染。结论:本研究提示细菌裂解物可能对预防RTIs具有临床益处。需要更多涉及更大队列的研究来验证OM-85在预防老年人RTIs中的有效性。
{"title":"Efficacy of OM-85 in Recurrent Respiratory Tract Infections.","authors":"Pietro Gareri,&nbsp;Caterina Trevisan,&nbsp;Angela Marie Abbatecola,&nbsp;Alba Malara,&nbsp;Raffaele Antonelli Incalzi","doi":"10.2174/1574887118666230518112806","DOIUrl":"https://doi.org/10.2174/1574887118666230518112806","url":null,"abstract":"<p><strong>Background: </strong>In older patients, prevention of acute respiratory tract infections (RTIs) is challenging. Experimental studies have consistently underlined an immune-potentiating effect of the bacterial lysates product OM85, on both cellular and humoral responses.</p><p><strong>Objective: </strong>This work aimed to assess the potential efficacy of OM-85 for RTIs' prevention in older individuals.</p><p><strong>Methods: </strong>This explorative longitudinal study included 24 patients aged 65 years or older recruited in the GeroCovid Observational Study- home and outpatient care cohort. For the study purposes, we included 8 patients treated with OM-85 from December 2020 to June 2021 (group A), and a control group of 16 patients, matched for sex and age, who did not receive bacterial lysates (group B). RTIs were recorded from the participants' medical documentation in an e-registry from March 2020 to December 2021.</p><p><strong>Results: </strong>In 2020, group A experienced a total of 8 RTIs, which affected 6 out of 8 patients (75%); group B reported 21 RTIs, with at least one event in 11 out of 16 patients (68.7%). In 2021, RTIs affected 2 out of 8 patients (25%) in group A (p < 0.02), and 13 out of 16 patients (81.2%) in group B (within this group, 5 patients had two RTIs). The RTIs' cumulative incidence over the observation period significantly differed between groups (66.7% in group A vs. 24.3% in group B; p < 0.002), as well as the decrease in RTIs frequency from 2020 to 2021. No patients in group A were affected by COVID-19 during the observation period, while among controls, two patients had SARS-CoV-2 infection, notwithstanding three doses of vaccine.</p><p><strong>Conclusion: </strong>This study suggests that bacterial lysates may provide clinical benefits for preventing RTIs. Additional research involving larger cohorts is required to verify the effectiveness of OM-85 in preventing RTIs in older adults.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10197558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease. 评估炎症性肠病患者性健康的患者报告结果
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-12-20 DOI: 10.2174/1574887117666220630114054
Daniela Pugliese, Laura Parisio, Tommaso Schepis, Giuseppe Privitera, Valentin Calvez, Antonio Gasbarrini, Alessandro Armuzzi

Patients affected by inflammatory bowel disease (IBD) frequently report impaired quality of sexual life and complain of sexual dysfunctions. Both disease-specific features and psychological factors can be held responsible for these conditions. However, sexuality and all matters relating to sexual health are often wrongfully considered unrelated to IBD and, therefore, overlooked during medical visits. To overcome these difficulties and to best assess patients' perceptions about their sexual health status, the use of patient-reported outcomes (PROs) could represent a valid strategy. In real-world studies, several non-IBD specific questionnaires, exploring different domains of sexuality, have been applied and validated for the IBD population. This review summarizes the available evidence on sexual health among IBD patients and the data supporting the application of PROs to screen the quality of sexual life, as well as the rate and types of sexual dysfunctions, among IBD patients.

受炎症性肠病(IBD)影响的患者经常报告性生活质量受损并抱怨性功能障碍。疾病特异性特征和心理因素都可能导致这些情况。然而,性行为和所有与性健康有关的问题往往被错误地认为与IBD无关,因此在就诊时被忽视。为了克服这些困难并最好地评估患者对其性健康状况的看法,使用患者报告的结果(PROs)可能是一种有效的策略。在现实世界的研究中,一些非IBD特异性问卷,探索不同的性领域,已经应用并验证了IBD人群。本文综述了有关IBD患者性健康的现有证据,以及支持应用pro筛查IBD患者性生活质量、性功能障碍发生率和类型的数据。
{"title":"Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease.","authors":"Daniela Pugliese,&nbsp;Laura Parisio,&nbsp;Tommaso Schepis,&nbsp;Giuseppe Privitera,&nbsp;Valentin Calvez,&nbsp;Antonio Gasbarrini,&nbsp;Alessandro Armuzzi","doi":"10.2174/1574887117666220630114054","DOIUrl":"https://doi.org/10.2174/1574887117666220630114054","url":null,"abstract":"<p><p>Patients affected by inflammatory bowel disease (IBD) frequently report impaired quality of sexual life and complain of sexual dysfunctions. Both disease-specific features and psychological factors can be held responsible for these conditions. However, sexuality and all matters relating to sexual health are often wrongfully considered unrelated to IBD and, therefore, overlooked during medical visits. To overcome these difficulties and to best assess patients' perceptions about their sexual health status, the use of patient-reported outcomes (PROs) could represent a valid strategy. In real-world studies, several non-IBD specific questionnaires, exploring different domains of sexuality, have been applied and validated for the IBD population. This review summarizes the available evidence on sexual health among IBD patients and the data supporting the application of PROs to screen the quality of sexual life, as well as the rate and types of sexual dysfunctions, among IBD patients.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10523230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing the Effects of Pregabalin and Clonidine on Postoperative Pain in Tonsillectomy: A Randomized, Double-Blind, Prospective Clinical Trial. 比较普瑞巴林和氯硝柳胺对扁桃体切除术术后疼痛的影响:随机、双盲、前瞻性临床试验。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-09-22 DOI: 10.2174/1574887117666220922092953
Shahryar Sane, Rahman Abbasi Vash, Nazila Rahmani, Hadi Talebi, Parang Golabi, Farid Kalashipour, Poneh Heidari, Mohammad-Foad Hatami, Behzad Kazemi Haki, Shabnam Morwati

Background: Tonsillectomy is one of the most common surgical procedures. This study compared the effect of Pregabalin and Clonidine on postoperative pain in adult patients undergoing elective tonsillectomy.

Methods: This randomized, double-blind, prospective clinical trial was conducted among 92 patients aged 20 to 50. The clonidine group (C) was given 150 µg of clonidine tablet 90 minutes before surgery, and the pregabalin group (P) was given 300 mg of pregabalin tablet 90 minutes before surgery. The results were analyzed by SPSS 25, and statistical analysis consisted of chisquare, T-test, and χ2 tests, and a p-value less than 0.05 was considered significant.

Results: The mean pain score and analgesic consumption scores in the pregabalin group were lower than in the clonidine group. According to the t-test, there was a significant difference between the two groups regarding pain score and analgesic consumption (p <0.05). Hemodynamic variation in both groups had no significant differences (p >0.05).

Conclusion: The present study showed that pregabalin reduced postoperative pain and analgesic consumption more effectively than clonidine.

背景:扁桃体切除术是最常见的外科手术之一:扁桃体切除术是最常见的外科手术之一。本研究比较了普瑞巴林和氯硝柳胺对接受扁桃体切除术的成年患者术后疼痛的影响:这项随机、双盲、前瞻性临床试验在 92 名 20 至 50 岁的患者中进行。克洛尼定组(C)在手术前 90 分钟服用 150 微克克洛尼定片,普瑞巴林组(P)在手术前 90 分钟服用 300 毫克普瑞巴林片。结果采用 SPSS 25 进行分析,统计分析包括方差分析、T 检验和 χ2 检验,P 值小于 0.05 为差异有显著性:普瑞巴林组的平均疼痛评分和镇痛药消耗评分均低于氯硝柳胺组。根据 t 检验,两组在疼痛评分和镇痛药消耗量方面存在显著差异(P 0.05):本研究表明,普瑞巴林比氯尼替丁更有效地减轻了术后疼痛和镇痛药用量。
{"title":"Comparing the Effects of Pregabalin and Clonidine on Postoperative Pain in Tonsillectomy: A Randomized, Double-Blind, Prospective Clinical Trial.","authors":"Shahryar Sane, Rahman Abbasi Vash, Nazila Rahmani, Hadi Talebi, Parang Golabi, Farid Kalashipour, Poneh Heidari, Mohammad-Foad Hatami, Behzad Kazemi Haki, Shabnam Morwati","doi":"10.2174/1574887117666220922092953","DOIUrl":"10.2174/1574887117666220922092953","url":null,"abstract":"<p><strong>Background: </strong>Tonsillectomy is one of the most common surgical procedures. This study compared the effect of Pregabalin and Clonidine on postoperative pain in adult patients undergoing elective tonsillectomy.</p><p><strong>Methods: </strong>This randomized, double-blind, prospective clinical trial was conducted among 92 patients aged 20 to 50. The clonidine group (C) was given 150 µg of clonidine tablet 90 minutes before surgery, and the pregabalin group (P) was given 300 mg of pregabalin tablet 90 minutes before surgery. The results were analyzed by SPSS 25, and statistical analysis consisted of chisquare, T-test, and χ2 tests, and a p-value less than 0.05 was considered significant.</p><p><strong>Results: </strong>The mean pain score and analgesic consumption scores in the pregabalin group were lower than in the clonidine group. According to the t-test, there was a significant difference between the two groups regarding pain score and analgesic consumption (p <0.05). Hemodynamic variation in both groups had no significant differences (p >0.05).</p><p><strong>Conclusion: </strong>The present study showed that pregabalin reduced postoperative pain and analgesic consumption more effectively than clonidine.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33481369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of age and gender disparity on CD4+ cell counts to control disease progression using specific HAART in HIV-1 positive patients: A case-control study. 年龄和性别差异对 HIV-1 阳性患者使用特定 HAART 控制疾病进展的 CD4+ 细胞计数的影响:病例对照研究。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-08-17 DOI: 10.2174/1574887117666220817123002
Aakansha Singh, Manoj Kumar, Ashok K Singh, Neeraj Verma

Background: Highly Active Antiretroviral Therapy (HAART) is composed of several drugs in the antiretroviral class to better treat human immunodeficiency virus type 1 (HIV-1) patients. The estimation of CD4+ T cell counts and HIV-1 viral load in plasma is required to evaluate the treatment success of a specific HAART.

Methodology: The study included the effects of NRTIs (nucleoside reverse transcriptase inhibitors) and novel protease inhibitors (HAART) on normal control subjects and HIV-1 positive subjects from SGPGIMS, Lucknow, with different age groups and genders. Furthermore, the study was conducted by the estimation of HIV through ELISA, measurement of absolute CD4+ cell count, and the measurement of viral load through qRT-PCR. Furthermore, NRTIs (Retrovir and Epivir) were administered orally one tablet daily in the morning followed by newly FDA-approved protease inhibitors (fosamprenavir and darunavir) orally in the evening at the same dose. Furthermore, CD4+T cell counts and HIV-1 viral load were investigated and correlated in patients with different genders and age groups.

Result: Administration of NRTIs and novel protease inhibitors (HAART) in HIV patients had a significant effect on the CD4+ cell count in various age intervals among males and females. The mean comparison of viral load distribution based on gender in CD4 +ve patients in the case group exhibited a viral load higher in females compared to males, indicating a statistically significant difference between males and females (p<0.05). A notable association between virological and immunological parameters was observed with a reciprocal relationship between viral load and CD4 cell count in CD4 +ve patients, demonstrating multiple correlation coefficients with an R-value of 0.853.

Conclusion: The administration of specific HAART (NRTIs and novel protease inhibitors) in HIV patients had a notable improvement in the CD4+ cell count and viral load with significant age and gender disparity.

背景:高活性抗逆转录病毒疗法(HAART高活性抗逆转录病毒疗法(HAART)由多种抗逆转录病毒类药物组成,旨在更好地治疗1型人类免疫缺陷病毒(HIV-1)患者。评估特定 HAART 的治疗成功与否,需要估算血浆中 CD4+ T 细胞计数和 HIV-1 病毒载量:研究包括 NRTIs(核苷酸逆转录酶抑制剂)和新型蛋白酶抑制剂(HAART)对正常对照组和勒克瑙 SGPGIMS 的 HIV-1 阳性受试者不同年龄组和性别的影响。此外,该研究还通过酶联免疫吸附试验(ELISA)估算艾滋病毒感染率,测量 CD4+ 细胞绝对计数,以及通过 qRT-PCR 测量病毒载量。此外,每天早上口服一片 NRTIs(Retrovir 和 Epivir),晚上以相同剂量口服美国 FDA 批准的新蛋白酶抑制剂(福沙那韦和达鲁那韦)。此外,还对不同性别和年龄组患者的 CD4+T 细胞计数和 HIV-1 病毒载量进行了调查和相关性分析:结果:HIV 患者服用 NRTIs 和新型蛋白酶抑制剂(HAART)对不同年龄段男性和女性的 CD4+ 细胞计数有显著影响。病例组 CD4+ve 患者基于性别的病毒载量分布平均值比较显示,女性的病毒载量高于男性,这表明男性和女性之间存在显著的统计学差异(p):对艾滋病患者使用特定的 HAART(NRTIs 和新型蛋白酶抑制剂)可明显改善 CD4+ 细胞计数和病毒载量,但存在明显的年龄和性别差异。
{"title":"Impact of age and gender disparity on CD4+ cell counts to control disease progression using specific HAART in HIV-1 positive patients: A case-control study.","authors":"Aakansha Singh, Manoj Kumar, Ashok K Singh, Neeraj Verma","doi":"10.2174/1574887117666220817123002","DOIUrl":"10.2174/1574887117666220817123002","url":null,"abstract":"<p><strong>Background: </strong>Highly Active Antiretroviral Therapy (HAART) is composed of several drugs in the antiretroviral class to better treat human immunodeficiency virus type 1 (HIV-1) patients. The estimation of CD4+ T cell counts and HIV-1 viral load in plasma is required to evaluate the treatment success of a specific HAART.</p><p><strong>Methodology: </strong>The study included the effects of NRTIs (nucleoside reverse transcriptase inhibitors) and novel protease inhibitors (HAART) on normal control subjects and HIV-1 positive subjects from SGPGIMS, Lucknow, with different age groups and genders. Furthermore, the study was conducted by the estimation of HIV through ELISA, measurement of absolute CD4+ cell count, and the measurement of viral load through qRT-PCR. Furthermore, NRTIs (Retrovir and Epivir) were administered orally one tablet daily in the morning followed by newly FDA-approved protease inhibitors (fosamprenavir and darunavir) orally in the evening at the same dose. Furthermore, CD4+T cell counts and HIV-1 viral load were investigated and correlated in patients with different genders and age groups.</p><p><strong>Result: </strong>Administration of NRTIs and novel protease inhibitors (HAART) in HIV patients had a significant effect on the CD4+ cell count in various age intervals among males and females. The mean comparison of viral load distribution based on gender in CD4 +ve patients in the case group exhibited a viral load higher in females compared to males, indicating a statistically significant difference between males and females (p<0.05). A notable association between virological and immunological parameters was observed with a reciprocal relationship between viral load and CD4 cell count in CD4 +ve patients, demonstrating multiple correlation coefficients with an R-value of 0.853.</p><p><strong>Conclusion: </strong>The administration of specific HAART (NRTIs and novel protease inhibitors) in HIV patients had a notable improvement in the CD4+ cell count and viral load with significant age and gender disparity.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40622249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring Mood and Anxiety Disorders by Patient Reported Outcomes in Inflammatory Bowel Disease: A Literature Review Update. 通过患者报告结果衡量炎症性肠病患者的情绪和焦虑障碍:最新文献综述。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-28 DOI: 10.2174/1574887117666220628151256
Rocco Spagnuolo, Antonio Basile, Alessandro Corea, Francesco Salvatore Iaquinta, Nataša Milić, Patrizia Doldo, Francesco Luzza, Ludovico Abenavoli

Background Anxiety and depression are the most common psychological disorders found in Inflammatory Bowel Disease (IBD) patients. Accurate measuring of these disorders should be proposed for a prompt management. Patient-reported outcome measurements (PROMs) allow patients to self-report their psychological symptoms. Objective To highlight the presence of PROMs measuring anxiety and depression in IBD setting evaluating the most used psychometric tools. Methods We reviewed the literature from 2010 up to September 2021. Articles on adult IBD patients assessing depression and anxiety by PROMs in English language were included. Results Thirty-six studies, including 11 psychometric tools were found. Hospital Anxiety and Depression Scale (21 studies), Beck Depression Inventory II (5 studies), Spielberg State-Trait Anxiety Inventory (3 studies), Patient-Reported Outcomes Measurement Information System (3 studies), Symptom Checklist-90 (2 studies), Euro Quality of Life (2 studies) mostly used psychometric tools for anxiety and depression in IBD settings. Conclusion Our review analyzed psychometric tools used for PROMs evaluating anxiety and depression in IBD setting. No chronological differences have emerged, all have been used in the last ten years, highlighting a lack of specificity. The strong association between IBD and mood disorders suggests that clinicians should consider the evaluation of depression and anxiety as integral parts of IBD clinical care. It is essential to identify tools enabling these items to be detected better. A global view of IBD patients, accounting not only for physical but also for psychical symptoms with an early and feasible assessment of unrecognized psychiatric disorders, can have a strong impact on their management strategy.

背景焦虑和抑郁是炎症性肠病(IBD)患者最常见的心理障碍。应建议对这些心理障碍进行准确测量,以便及时进行治疗。患者报告结果测量法(PROMs)允许患者自我报告其心理症状。目的 通过评估最常用的心理测量工具,强调在 IBD 环境中测量焦虑和抑郁的 PROMs 的存在。方法 我们回顾了 2010 年至 2021 年 9 月的文献。纳入了关于成年 IBD 患者使用 PROM 评估抑郁和焦虑的英文文章。结果 找到了 36 项研究,包括 11 种心理测量工具。医院焦虑抑郁量表(21 项研究)、贝克抑郁量表 II(5 项研究)、斯皮尔伯格状态-特质焦虑量表(3 项研究)、患者报告结果测量信息系统(3 项研究)、症状检查表-90(2 项研究)、欧洲生活质量(2 项研究)是 IBD 环境中最常用的焦虑和抑郁心理测量工具。结论 我们的综述分析了用于评估 IBD 环境中焦虑和抑郁的 PROM 的心理测量工具。所有这些工具都是在过去十年中使用的,并没有出现时间上的差异,这说明这些工具缺乏特异性。IBD 与情绪障碍之间的密切联系表明,临床医生应将抑郁和焦虑的评估视为 IBD 临床护理的组成部分。有必要确定能够更好地检测这些项目的工具。对 IBD 患者进行全面观察,不仅要考虑躯体症状,还要考虑精神症状,并对未被发现的精神障碍进行早期可行的评估,这将对患者的管理策略产生重大影响。
{"title":"Measuring Mood and Anxiety Disorders by Patient Reported Outcomes in Inflammatory Bowel Disease: A Literature Review Update.","authors":"Rocco Spagnuolo, Antonio Basile, Alessandro Corea, Francesco Salvatore Iaquinta, Nataša Milić, Patrizia Doldo, Francesco Luzza, Ludovico Abenavoli","doi":"10.2174/1574887117666220628151256","DOIUrl":"10.2174/1574887117666220628151256","url":null,"abstract":"<p><p>Background Anxiety and depression are the most common psychological disorders found in Inflammatory Bowel Disease (IBD) patients. Accurate measuring of these disorders should be proposed for a prompt management. Patient-reported outcome measurements (PROMs) allow patients to self-report their psychological symptoms. Objective To highlight the presence of PROMs measuring anxiety and depression in IBD setting evaluating the most used psychometric tools. Methods We reviewed the literature from 2010 up to September 2021. Articles on adult IBD patients assessing depression and anxiety by PROMs in English language were included. Results Thirty-six studies, including 11 psychometric tools were found. Hospital Anxiety and Depression Scale (21 studies), Beck Depression Inventory II (5 studies), Spielberg State-Trait Anxiety Inventory (3 studies), Patient-Reported Outcomes Measurement Information System (3 studies), Symptom Checklist-90 (2 studies), Euro Quality of Life (2 studies) mostly used psychometric tools for anxiety and depression in IBD settings. Conclusion Our review analyzed psychometric tools used for PROMs evaluating anxiety and depression in IBD setting. No chronological differences have emerged, all have been used in the last ten years, highlighting a lack of specificity. The strong association between IBD and mood disorders suggests that clinicians should consider the evaluation of depression and anxiety as integral parts of IBD clinical care. It is essential to identify tools enabling these items to be detected better. A global view of IBD patients, accounting not only for physical but also for psychical symptoms with an early and feasible assessment of unrecognized psychiatric disorders, can have a strong impact on their management strategy.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40411214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PSSD and biologic therapy: Real-life data in 417 patients with moderate to severe psoriasis. PSSD 和生物疗法:417 名中度至重度银屑病患者的真实生活数据。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-23 DOI: 10.2174/1574887117666220623161751
Ilaria Proietti, Nicoletta Bernardini, Nevena Skroza, Alessandra Mambrin, Ersilia Tolino, Anna Marchesiello, Federica Marraffa, Giovanni Rossi, Salvatore Volpe, Concetta Potenza

Background: Psoriasis is a chronic relapsing immune-mediated disease leading to a strong impact on patient's quality of life. The treatment of psoriasis has undergone a revolution with the advent of biologic therapies. Currently, Psoriasis Area and Severity Index [PASI] and Dermatology Life Quality Index [DLQI] scores are in use to assess the overall severity of pathology. A new self- administered questionnaire, the Psoriasis Symptoms and Signs Diary (PSSD), assesses severity of six psoriasis symptoms (itch, skin tightness, burning, stinging, and pain,) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding).

Objective: To evaluate and compare the efficacy of biologic therapies through PSSD in patients with moderate to severe psoriasis Methods: The PSSD questionnaire was administered to all the patients at the beginning and after 6 months of biologic therapy (anti-TNFalpha, anti- IL17, anti-IL23, anti-IL12/23 and phhosphodiesterase-4 Inhibitors).

Results: The study population included 417 adult patients with moderate to severe psoriasis in treatment with biologic drugs. All the drugs contributed to a significant improvement of mean total PSSD at t 24; anti-IL17 and anti-IL23 led to a significantly greater reduction at t 24 mean PSSD when compared to other therapies.

Conclusion: The PSSD, is a new validated instrument useful for capturing psoriasis patient's quality of life and evaluating treatments efficacy. In our study this score has been useful to put in evidence significant differences between biologic drugs.

背景:银屑病是一种慢性复发性免疫介导疾病,严重影响患者的生活质量。随着生物疗法的出现,银屑病的治疗经历了一场革命。目前,银屑病面积和严重程度指数(PASI)和皮肤病生活质量指数(DLQI)被用来评估病变的整体严重程度。一种新的自我管理问卷--银屑病症状和体征日记(PSSD)可评估六种银屑病症状(瘙痒、皮肤紧绷、灼热、刺痛和疼痛)和五种体征(干燥、皲裂、脱屑、脱落/剥落、发红和出血)的严重程度:通过 PSSD 评估和比较生物疗法对中重度银屑病患者的疗效:所有患者在接受生物疗法(抗肿瘤坏死因子α、抗IL17、抗IL23、抗IL12/23和磷酸二酯酶-4抑制剂)之初和6个月后均接受了PSSD问卷调查:研究对象包括417名接受生物制剂治疗的中重度银屑病成年患者。与其他疗法相比,抗IL17和抗IL23能显著降低24小时的平均总PSSD:PSSD是一种新的有效工具,可用于了解银屑病患者的生活质量和评估治疗效果。在我们的研究中,该评分有助于证明生物药物之间的显著差异。
{"title":"PSSD and biologic therapy: Real-life data in 417 patients with moderate to severe psoriasis.","authors":"Ilaria Proietti, Nicoletta Bernardini, Nevena Skroza, Alessandra Mambrin, Ersilia Tolino, Anna Marchesiello, Federica Marraffa, Giovanni Rossi, Salvatore Volpe, Concetta Potenza","doi":"10.2174/1574887117666220623161751","DOIUrl":"10.2174/1574887117666220623161751","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic relapsing immune-mediated disease leading to a strong impact on patient's quality of life. The treatment of psoriasis has undergone a revolution with the advent of biologic therapies. Currently, Psoriasis Area and Severity Index [PASI] and Dermatology Life Quality Index [DLQI] scores are in use to assess the overall severity of pathology. A new self- administered questionnaire, the Psoriasis Symptoms and Signs Diary (PSSD), assesses severity of six psoriasis symptoms (itch, skin tightness, burning, stinging, and pain,) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding).</p><p><strong>Objective: </strong>To evaluate and compare the efficacy of biologic therapies through PSSD in patients with moderate to severe psoriasis Methods: The PSSD questionnaire was administered to all the patients at the beginning and after 6 months of biologic therapy (anti-TNFalpha, anti- IL17, anti-IL23, anti-IL12/23 and phhosphodiesterase-4 Inhibitors).</p><p><strong>Results: </strong>The study population included 417 adult patients with moderate to severe psoriasis in treatment with biologic drugs. All the drugs contributed to a significant improvement of mean total PSSD at t 24; anti-IL17 and anti-IL23 led to a significantly greater reduction at t 24 mean PSSD when compared to other therapies.</p><p><strong>Conclusion: </strong>The PSSD, is a new validated instrument useful for capturing psoriasis patient's quality of life and evaluating treatments efficacy. In our study this score has been useful to put in evidence significant differences between biologic drugs.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40394225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and Acute Treatment of Ischemic Stroke. 缺血性中风的诊断和急性治疗。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-17 DOI: 10.2174/1574887117666220617103114
Ernesto Cristiano Lauritano, Federica Nicoletta Sepe, Maria Carmela Mascolo, Riccardo Boverio, Luigi Ruiz

Stroke is defined as an acute cerebrovascular accident characterized by an interruption of vascular supply lasting more than 24 hours. Therapeutic goal, reassumed at the well-known "time is brain", is strictly focused on achieving timely restoration of cerebral blood flow at risk of infarction to reduce neurological complications. Consequently, time to treatment is the most important determinant of the efficacy of reperfusion. Current guidelines strongly recommend the use of intravenous thrombolysis with tissue plasminogen activator and endovascular thrombectomy to reach that goal. These therapies allow to obtain 1.9 million neurons saved per each minute of onset-to-reperfusion time and 4.2 days of extra healthy life and are crucial in the reduction of mortality and morbidity of ischemic stroke. Multidisciplinary collaboration involving a coordinated prehospital management and stroke team composed of physicians with expertise in emergency medicine, neurologists, radiologists, nurses, technicians, and laboratory personnel are essential for rapid triage and should guide clinical decisions to deliver the appropriate reperfusion therapy for each patient.

脑卒中是指血管供应中断超过 24 小时的急性脑血管意外。众所周知,"时间就是大脑",治疗目标严格集中在及时恢复有梗死风险的脑血流,以减少神经系统并发症。因此,治疗时间是决定再灌注疗效的最重要因素。目前的指南强烈建议使用组织凝血酶原激活剂静脉溶栓和血管内血栓切除术来实现这一目标。这些疗法可以在发病到再灌注的每一分钟内挽救 190 万个神经元,延长 4.2 天的健康寿命,对降低缺血性中风的死亡率和发病率至关重要。由急诊科医生、神经科医生、放射科医生、护士、技术人员和实验室人员组成的院前协调管理和中风团队的多学科合作对于快速分诊至关重要,并应指导临床决策,为每位患者提供适当的再灌注治疗。
{"title":"Diagnosis and Acute Treatment of Ischemic Stroke.","authors":"Ernesto Cristiano Lauritano, Federica Nicoletta Sepe, Maria Carmela Mascolo, Riccardo Boverio, Luigi Ruiz","doi":"10.2174/1574887117666220617103114","DOIUrl":"10.2174/1574887117666220617103114","url":null,"abstract":"<p><p>Stroke is defined as an acute cerebrovascular accident characterized by an interruption of vascular supply lasting more than 24 hours. Therapeutic goal, reassumed at the well-known \"time is brain\", is strictly focused on achieving timely restoration of cerebral blood flow at risk of infarction to reduce neurological complications. Consequently, time to treatment is the most important determinant of the efficacy of reperfusion. Current guidelines strongly recommend the use of intravenous thrombolysis with tissue plasminogen activator and endovascular thrombectomy to reach that goal. These therapies allow to obtain 1.9 million neurons saved per each minute of onset-to-reperfusion time and 4.2 days of extra healthy life and are crucial in the reduction of mortality and morbidity of ischemic stroke. Multidisciplinary collaboration involving a coordinated prehospital management and stroke team composed of physicians with expertise in emergency medicine, neurologists, radiologists, nurses, technicians, and laboratory personnel are essential for rapid triage and should guide clinical decisions to deliver the appropriate reperfusion therapy for each patient.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39999403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic Encephalopathy by Manganese Deposition: A Case Report and a Review of Literature. 锰沉积引起的肝性脑病:病例报告和文献综述。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-17 DOI: 10.2174/1574887117666220617104539
Ludovico Abenavoli, Giulia Fabiano, Anna Caterina Procopio, Isabella Aquila, Rinaldo Pellicano, Stefania Barone, Maurizio Morelli, Francesco Luzza

Background: Hepatic encephalopathy is defined as a spectrum of neuropsychiatric disorders in patients with liver dysfunction, usually cirrhosis, after exclusion of brain disease. This study reports the role of manganese in brain alterations and therefore in clinical manifestations of hepatic encephalopathy.

Case presentation: Male patient, 67 years old, suffering from alcoholic liver cirrhosis and two previous episodes of hepatic encephalopathy, developed drowsiness, asterixis, amnesia, disorientation in time and space, and psychomotor retardation. Brain MRI without contrast showed: initial signs of cerebral atrophy, a hyperintense signal of globi pallidi and bilateral substantia nigra. The hyperintense signal of globi pallidi is the result of manganese deposition in the brain.

Conclusion: The case report presented supports the data reported in the literature indicating that the increase in plasma manganese levels in subjects with liver dysfunction is correlated with the onset of extrapyramidal symptoms.

背景:肝性脑病是指肝功能异常(通常为肝硬化)患者在排除脑部疾病后出现的一系列神经精神障碍。本研究报告了锰在脑部改变中的作用,以及锰在肝性脑病临床表现中的作用:男性患者,67 岁,患有酒精性肝硬化,曾两次发作肝性脑病,出现嗜睡、眼花、健忘、时空错乱和精神运动迟滞。无造影剂的脑部磁共振成像显示:最初的脑萎缩迹象、苍白球和双侧黑质的高强度信号。苍白球高信号是锰在大脑中沉积的结果:本病例报告支持文献报道的数据,即肝功能异常患者血浆锰水平的升高与锥体外系症状的出现相关。
{"title":"Hepatic Encephalopathy by Manganese Deposition: A Case Report and a Review of Literature.","authors":"Ludovico Abenavoli, Giulia Fabiano, Anna Caterina Procopio, Isabella Aquila, Rinaldo Pellicano, Stefania Barone, Maurizio Morelli, Francesco Luzza","doi":"10.2174/1574887117666220617104539","DOIUrl":"10.2174/1574887117666220617104539","url":null,"abstract":"<p><strong>Background: </strong>Hepatic encephalopathy is defined as a spectrum of neuropsychiatric disorders in patients with liver dysfunction, usually cirrhosis, after exclusion of brain disease. This study reports the role of manganese in brain alterations and therefore in clinical manifestations of hepatic encephalopathy.</p><p><strong>Case presentation: </strong>Male patient, 67 years old, suffering from alcoholic liver cirrhosis and two previous episodes of hepatic encephalopathy, developed drowsiness, asterixis, amnesia, disorientation in time and space, and psychomotor retardation. Brain MRI without contrast showed: initial signs of cerebral atrophy, a hyperintense signal of globi pallidi and bilateral substantia nigra. The hyperintense signal of globi pallidi is the result of manganese deposition in the brain.</p><p><strong>Conclusion: </strong>The case report presented supports the data reported in the literature indicating that the increase in plasma manganese levels in subjects with liver dysfunction is correlated with the onset of extrapyramidal symptoms.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39999404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Value of Rox Index to Predict Intubation and Intensive Care Unit Outcome in Patients with Respiratory Failure. Rox指数预测呼吸衰竭患者插管和重症监护室结果的价值。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-06 DOI: 10.2174/1574887117666220606114549
Ayshan Mammadova, Esra Eriş, Zeynep Sena Solmaz, Ayşe Taşçı Kara, Aydın Atasoy, Gül Gürsel

Background: Recent literature suggests that the respiratory rate oxygenation (ROX) index may be a useful parameter in predicting intubation indication in hypoxemic patients.

Objective: In this study, we evaluated the accuracy of the ROX index in predicting intubation, length of stay in the ICU, and mortality in ICU patients with hypoxemic respiratory failure with and without hypercapnia.

Methods: Single-centre retrospective cohort study of 290 patients, with a preliminary diagnosis of respiratory failure, who were treated with low flow oxygen systems. Demographics, medical history, clinical, laboratory, treatment, and prognostic data were obtained from the electronic records of the hospital. The ROX index was calculated at the time of ICU admission.

Results: Thirty-seven percent of non-hypercapnic and 69% of hypercapnic patients were intubated (p:0.005). In hypercapnic patients, ROX: 6.9 had highest sensitivity (81%) and specificity (65%) values for intubation (p:0.005). In non-hypercapnic patients, ROX: 6.2 had the highest sensitivity (81%) and specificity (40%) values. While 11% of hypercapnic patients and 30% of non-hypercapnic patients were died (p:0.05), 22% of hypercapnic patients and 33% of non-hypercapnic patients stayed in the ICU longer than 14 days (p:0.044). The highest sensitivity and specificity values were found for mortality in hypercapnic patients; for ROX value of 5.94 (sensitivity:86%, specificity:61%) and for ICU stay longer than 14 days; for ROX value of 7.4 (sensitivity:71%, specificity:68%).

Conclusion: Results of our study suggest that ROX index calculated during ICU admission can be helpful in predicting intubation indication and length of ICU stay in patients with respiratory failure and hypercapnia may influence the cutoff values.

背景最近的文献表明,呼吸速率氧合(ROX)指数可能是预测低氧血症患者插管指征的有用参数。目的在本研究中,我们评估了ROX指数在预测伴有和不伴有高碳酸血症的低氧性呼吸衰竭ICU患者的插管、ICU住院时间和死亡率方面的准确性。方法对290名初步诊断为呼吸衰竭并接受低流量氧气系统治疗的患者进行单中心回顾性队列研究。从医院的电子记录中获得人口统计学、病史、临床、实验室、治疗和预后数据。ROX指数在入住ICU时进行计算。结果约有7%的非高碳酸血症患者和69%的高碳酸血症病人插管(p:0.005)。在高碳酸血症的患者中,ROX:6.9对插管的敏感性(81%)和特异性(65%)最高(p:0.005)。在非高碳酸症的病人中,ROX:6.2的敏感性(81%)和特异度(40%)最高。11%的高碳酸血症和30%的非高碳酸血症患者死亡(p:0.05),22%的高碳酸症患者和33%的非高二氧化碳血症患者在ICU停留时间超过14天(p:0.044);ROX值为5.94(敏感性:86%,特异性:61%),ICU住院时间超过14天;ROX值为7.4(敏感性:71%,特异性:68%)。结论我们的研究结果表明,在ICU入院期间计算的ROX指数有助于预测呼吸衰竭和高碳酸血症患者的插管指征和ICU住院时间可能会影响临界值。
{"title":"Value of Rox Index to Predict Intubation and Intensive Care Unit Outcome in Patients with Respiratory Failure.","authors":"Ayshan Mammadova, Esra Eriş, Zeynep Sena Solmaz, Ayşe Taşçı Kara, Aydın Atasoy, Gül Gürsel","doi":"10.2174/1574887117666220606114549","DOIUrl":"10.2174/1574887117666220606114549","url":null,"abstract":"<p><strong>Background: </strong>Recent literature suggests that the respiratory rate oxygenation (ROX) index may be a useful parameter in predicting intubation indication in hypoxemic patients.</p><p><strong>Objective: </strong>In this study, we evaluated the accuracy of the ROX index in predicting intubation, length of stay in the ICU, and mortality in ICU patients with hypoxemic respiratory failure with and without hypercapnia.</p><p><strong>Methods: </strong>Single-centre retrospective cohort study of 290 patients, with a preliminary diagnosis of respiratory failure, who were treated with low flow oxygen systems. Demographics, medical history, clinical, laboratory, treatment, and prognostic data were obtained from the electronic records of the hospital. The ROX index was calculated at the time of ICU admission.</p><p><strong>Results: </strong>Thirty-seven percent of non-hypercapnic and 69% of hypercapnic patients were intubated (p:0.005). In hypercapnic patients, ROX: 6.9 had highest sensitivity (81%) and specificity (65%) values for intubation (p:0.005). In non-hypercapnic patients, ROX: 6.2 had the highest sensitivity (81%) and specificity (40%) values. While 11% of hypercapnic patients and 30% of non-hypercapnic patients were died (p:0.05), 22% of hypercapnic patients and 33% of non-hypercapnic patients stayed in the ICU longer than 14 days (p:0.044). The highest sensitivity and specificity values were found for mortality in hypercapnic patients; for ROX value of 5.94 (sensitivity:86%, specificity:61%) and for ICU stay longer than 14 days; for ROX value of 7.4 (sensitivity:71%, specificity:68%).</p><p><strong>Conclusion: </strong>Results of our study suggest that ROX index calculated during ICU admission can be helpful in predicting intubation indication and length of ICU stay in patients with respiratory failure and hypercapnia may influence the cutoff values.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47693884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reviews on recent clinical trials
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1